Pitch Engine

Times Advertising


.

Why Headless CMS Is Critical for Cross-Border Brand Consistency: Building One Global Voice Across Many Markets

The larger a brand grows, the easier it becomes to jeopardize consistent communications. Brand experiences are impacted across different languages, cultures, legalities and marketing strat...

Using Structured Content to Build Multi-Step Marketing Funnels: A Scalable Framework for Guided Conversion

Multi-step marketing funnels aim to take users from awareness to conversion and through subsequent stages. Where basic funnels capture all momentum on one landing page, modern marketing ef...

From Pages to Components: How Headless CMS Changes Content Strategy

For years, content strategy was all about pages. Websites were created, written, designed, and optimized one by one, with content closely connected to placement and presentation. It made s...

Supporting Real-Time Interfaces with API-First Content Systems

Real-time interfaces have changed user expectations across many digital solutions. From live data dashboards to conversational interfaces and collaborative platforms, in-app alerts and con...

Biosafety Cabinet vs Ductless Fume Hood: Engineering Safety in Modern Laboratories

Why Containment Equipment Defines Research Integrity The modern laboratory is an environment of controlled risks. Whether handling infectious microorganisms or volatile organic solvents, ...

How Small Businesses Can Compete With Big Brands In Media Coverage?

Corporations with massive marketing expenditures are no longer the sole beneficiaries of media exposure in the contemporary digital era. Small businesses now have access to tools, platforms...

香港,中国 - Media OutReach - 2016年10月5日 - 新元医疗基金（新元基金）宣布对Enable Injections, Inc. （以下简称"公司"或"Enable"）进行3000万美金的A轮投资。Enable 是一家总部位于美国辛辛那提市的医疗器械公司，致力于开发和制造可穿戴的新型注射医疗设备，使患者可自行注射大容量生物制剂。新元基金是该轮融资的牵头投资人，其他成员包括CincyTech，辛辛那提儿童医院医学中心，俄亥俄州创新基金和Cintrifuse。

 

Enable的价值体现在其科技平台技术可允许皮下注射高达50毫升的生物制剂。利用药物原有的包装，无需进行注射设备和药物的兼容性实验，从而降低研发风险、成本和上市时间。公司的注射器系统机制简单直接、私密性强，为患者提供最佳的用户体验。

 

Enable目前正与十多家制药公司进行合作谈判，并已与杰特贝林公司（CSL Behring）签订了开发和生产合同。本轮的投资将有助于公司进一步的业务拓展。

 

本次交易与新元基金一贯秉承投资于革新公司以有效改善现有医疗水平的理念相吻合。新元基金高级合伙人，宋红方（Ms. Simone Song）女士这样评论： "我们相信大容量注射器具有巨大的市场需求。对于提供高容量的生物制剂，Enable将会是改变标准治疗方式的先锋。我们对投资于Enable的技术有着十足的把握，能够为医疗界关键利益相关者都带来价值。"

 

Enable 首席执行官Mike Hooven表示： "新元基金广泛的人际关系网络及其对迅速发展的生物制药领域深入的了解，是对Enable这家拥有丰富医疗器械经验公司的完美补充。我们很高兴能与新元基金建立业务合作，让患者自行方便地使用大容量的生物制剂。"

 

公司商标

http://release.media-outreach.com/i/Download/4688

 

关于新元医疗基金

新元基金是一家2亿美元规模的风险投资基金，专注于全球医疗行业内拥有颠覆性技术的创新型公司。该基金由前高盛亚洲医疗健康行业主管宋红方女士创立。新元团队主要由生物医药领域的科学家和前高盛投资银行家构成。

Source http://www.media-outreach.com/release.php/View/2647#Contact